Jubilant Ingrevia Limited announced its financial results for the quarter ended December 31, 2025, with the Board recommending an interim dividend of 250%, translating to ₹2.5 per equity share. Total revenue for the quarter stood at ₹1,051 crore, a marginal decrease of 1% year-on-year and 6% quarter-on-quarter. Profit After Tax (PAT) after exceptional items was ₹47 crore, down 32% year-on-year and 33% quarter-on-quarter. Basic and Diluted EPS for the quarter was ₹3.0. The company highlighted sustained growth momentum in its Specialty Chemicals segment, driven by revenue expansion and a robust double-digit increase in EBITDA. The Nutrition business sustained a healthy trajectory of volume growth across all core products, while the Chemical Intermediates segment maintained market share and recorded year-on-year volume growth. Despite softer pricing across all three segments, strong volume growth helped offset the impact, resulting in stable overall business performance. EBITDA margin was maintained at 13%. For the nine-month period ended December 31, 2025, revenues increased by 3% to ₹3,210 crore, EBITDA rose by 8% to ₹436 crore, and PAT after exceptional items registered an 8% growth to ₹191 crore. This growth was achieved despite an amendment to the Indian Labor Code and an associated one-time exceptional expense. Looking ahead to Q4 FY26, Jubilant Ingrevia anticipates sustained growth momentum, driven by its Specialty Chemicals and Nutrition businesses, along with a partial recovery in the Acetyls portfolio. The company commissioned a new boiler at its Bharuch site to enhance operational efficiency and is on track to commence delivery of a major CDMO order in Q4 FY26. Construction has also begun on a new multipurpose plant in Gajraula. The company expects to gain market share in Europe and the US markets due to recent FTAs.
